Senazodan is a Ca2+ sensitiser, and also shows inhibition effect on PDE III. References: Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203. [2]. Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70.

纯度：≥98%

CAS：98326-32-0